#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=5. Microparticles as an Indicator of Disease Activity
1-1	0-2	5.	_	_	_	_
1-2	3-17	Microparticles	object[1]	new[1]	coref	2-1[0_1]
1-3	18-20	as	object[1]	new[1]	_	_
1-4	21-23	an	object[1]	new[1]	_	_
1-5	24-33	Indicator	object[1]	new[1]	_	_
1-6	34-36	of	object[1]	new[1]	_	_
1-7	37-44	Disease	object[1]|abstract|abstract[3]	new[1]|new|new[3]	coref|coref	3-12|3-12[13_3]
1-8	45-53	Activity	object[1]|abstract[3]	new[1]|new[3]	_	_

#Text=Microparticles have been attracting increasing attention as potential indicators of eukaryotic cell activation .
2-1	54-68	Microparticles	object	giv	ana	3-1
2-2	69-73	have	_	_	_	_
2-3	74-78	been	_	_	_	_
2-4	79-89	attracting	_	_	_	_
2-5	90-100	increasing	_	_	_	_
2-6	101-110	attention	abstract	new	_	_
2-7	111-113	as	_	_	_	_
2-8	114-123	potential	_	_	_	_
2-9	124-134	indicators	_	_	_	_
2-10	135-137	of	_	_	_	_
2-11	138-148	eukaryotic	event[7]	new[7]	_	_
2-12	149-153	cell	place|event[7]	new|new[7]	_	_
2-13	154-164	activation	event[7]	new[7]	_	_
2-14	165-166	.	_	_	_	_

#Text=They could provide valuable information on inflammatory processes in progress , disease activity , and the response to treatment as well as prognosis as a disease assessment indicator .
3-1	167-171	They	object	giv	coref	6-13[45_0]
3-2	172-177	could	_	_	_	_
3-3	178-185	provide	_	_	_	_
3-4	186-194	valuable	abstract[9]	new[9]	_	_
3-5	195-206	information	abstract[9]	new[9]	_	_
3-6	207-209	on	abstract[9]	new[9]	_	_
3-7	210-222	inflammatory	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-8	223-232	processes	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-9	233-235	in	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-10	236-244	progress	abstract[9]|abstract[10]|abstract	new[9]|new[10]|new	_	_
3-11	245-246	,	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-12	247-254	disease	abstract[9]|abstract[10]|abstract|abstract[13]	new[9]|new[10]|giv|giv[13]	coref|coref	3-26|4-17[24_13]
3-13	255-263	activity	abstract[9]|abstract[10]|abstract[13]	new[9]|new[10]|giv[13]	_	_
3-14	264-265	,	_	_	_	_
3-15	266-269	and	_	_	_	_
3-16	270-273	the	abstract[14]	new[14]	_	_
3-17	274-282	response	abstract[14]	new[14]	_	_
3-18	283-285	to	abstract[14]	new[14]	_	_
3-19	286-295	treatment	abstract[14]|abstract	new[14]|new	coref	14-6[129_0]
3-20	296-298	as	_	_	_	_
3-21	299-303	well	_	_	_	_
3-22	304-306	as	_	_	_	_
3-23	307-316	prognosis	abstract[16]	new[16]	_	_
3-24	317-319	as	abstract[16]	new[16]	_	_
3-25	320-321	a	abstract[16]	new[16]	_	_
3-26	322-329	disease	abstract[16]|abstract	new[16]|giv	coref	6-28
3-27	330-340	assessment	abstract[16]|abstract	new[16]|new	_	_
3-28	341-350	indicator	abstract[16]	new[16]	_	_
3-29	351-352	.	_	_	_	_

#Text=Hsu et al. demonstrated that release of MPs from platelets activated with collagen decreased considerably after the activity of kinase BTK was inhibited .
4-1	353-356	Hsu	person	new	_	_
4-2	357-359	et	_	_	_	_
4-3	360-363	al.	_	_	_	_
4-4	364-376	demonstrated	_	_	_	_
4-5	377-381	that	event[20]	new[20]	coref	5-22[37_20]
4-6	382-389	release	event[20]	new[20]	_	_
4-7	390-392	of	event[20]	new[20]	_	_
4-8	393-396	MPs	event[20]|object	new[20]|new	coref	7-5
4-9	397-401	from	_	_	_	_
4-10	402-411	platelets	object	new	_	_
4-11	412-421	activated	_	_	_	_
4-12	422-426	with	_	_	_	_
4-13	427-435	collagen	organization	new	_	_
4-14	436-445	decreased	_	_	_	_
4-15	446-458	considerably	_	_	_	_
4-16	459-464	after	_	_	_	_
4-17	465-468	the	abstract[24]	giv[24]	coref	6-27[51_24]
4-18	469-477	activity	abstract[24]	giv[24]	_	_
4-19	478-480	of	abstract[24]	giv[24]	_	_
4-20	481-487	kinase	abstract[24]|abstract|object[26]	giv[24]|new|new[26]	coref	5-9[0_26]
4-21	488-491	BTK	abstract[24]|object[26]	giv[24]|new[26]	_	_
4-22	492-495	was	_	_	_	_
4-23	496-505	inhibited	_	_	_	_
4-24	506-507	.	_	_	_	_

#Text=Reduction of PMPs numbers in other studies with BTK inhibitor in platelet cultures was associated with a decrease in production and the release of inflammatory cytokines IL-6 and IL-8 .
5-1	508-517	Reduction	abstract[27]	new[27]	coref	16-24[0_27]
5-2	518-520	of	abstract[27]	new[27]	_	_
5-3	521-525	PMPs	abstract[27]|abstract|quantity[29]	new[27]|new|new[29]	coref	16-11
5-4	526-533	numbers	abstract[27]|quantity[29]	new[27]|new[29]	_	_
5-5	534-536	in	abstract[27]|quantity[29]	new[27]|new[29]	_	_
5-6	537-542	other	abstract[27]|quantity[29]|event[30]	new[27]|new[29]|new[30]	coref	10-13[99_30]
5-7	543-550	studies	abstract[27]|quantity[29]|event[30]	new[27]|new[29]|new[30]	_	_
5-8	551-555	with	abstract[27]|quantity[29]|event[30]	new[27]|new[29]|new[30]	_	_
5-9	556-559	BTK	abstract[27]|quantity[29]|event[30]|object|object[32]	new[27]|new[29]|new[30]|giv|new[32]	_	_
5-10	560-569	inhibitor	abstract[27]|quantity[29]|event[30]|object[32]	new[27]|new[29]|new[30]|new[32]	_	_
5-11	570-572	in	abstract[27]|quantity[29]|event[30]|object[32]	new[27]|new[29]|new[30]|new[32]	_	_
5-12	573-581	platelet	abstract[27]|quantity[29]|event[30]|object[32]|place|object[34]	new[27]|new[29]|new[30]|new[32]|new|new[34]	coref	6-8
5-13	582-590	cultures	abstract[27]|quantity[29]|event[30]|object[32]|object[34]	new[27]|new[29]|new[30]|new[32]|new[34]	_	_
5-14	591-594	was	_	_	_	_
5-15	595-605	associated	_	_	_	_
5-16	606-610	with	_	_	_	_
5-17	611-612	a	event[35]	new[35]	coref	16-31[169_35]
5-18	613-621	decrease	event[35]	new[35]	_	_
5-19	622-624	in	event[35]	new[35]	_	_
5-20	625-635	production	event[35]|abstract	new[35]|new	coref	15-56[157_0]
5-21	636-639	and	event[35]	new[35]	_	_
5-22	640-643	the	event[35]|event[37]	new[35]|giv[37]	coref	15-53[155_37]
5-23	644-651	release	event[35]|event[37]	new[35]|giv[37]	_	_
5-24	652-654	of	event[35]|event[37]	new[35]|giv[37]	_	_
5-25	655-667	inflammatory	event[35]|event[37]|abstract[38]|event[39]	new[35]|giv[37]|new[38]|new[39]	_	_
5-26	668-677	cytokines	event[35]|event[37]|abstract[38]|event[39]	new[35]|giv[37]|new[38]|new[39]	_	_
5-27	678-682	IL-6	event[35]|event[37]|event[39]	new[35]|giv[37]|new[39]	_	_
5-28	683-686	and	event[35]|event[37]	new[35]|giv[37]	_	_
5-29	687-691	IL-8	event[35]|event[37]|event	new[35]|giv[37]|new	_	_
5-30	692-693	.	_	_	_	_

#Text=A considerable increase in the number of platelet , monocyte , and lymphocyte-derived microparticles ( CD3 , CD19 ) has been observed in RA patients with high disease activity . Rodrigez-Cario et al. examined the amount of circulating microparticles and their origin in 114 RA patients .
6-1	694-695	A	abstract[41]	new[41]	_	_
6-2	696-708	considerable	abstract[41]	new[41]	_	_
6-3	709-717	increase	abstract[41]	new[41]	_	_
6-4	718-720	in	abstract[41]	new[41]	_	_
6-5	721-724	the	abstract[41]|quantity[42]	new[41]|new[42]	_	_
6-6	725-731	number	abstract[41]|quantity[42]	new[41]|new[42]	_	_
6-7	732-734	of	abstract[41]|quantity[42]	new[41]|new[42]	_	_
6-8	735-743	platelet	abstract[41]|quantity[42]|object	new[41]|new[42]|giv	coref	7-7
6-9	744-745	,	abstract[41]|quantity[42]	new[41]|new[42]	_	_
6-10	746-754	monocyte	abstract[41]|quantity[42]|substance	new[41]|new[42]|new	_	_
6-11	755-756	,	abstract[41]|quantity[42]	new[41]|new[42]	_	_
6-12	757-760	and	abstract[41]|quantity[42]	new[41]|new[42]	_	_
6-13	761-779	lymphocyte-derived	abstract[41]|quantity[42]|abstract[45]	new[41]|new[42]|giv[45]	appos	6-16[0_45]
6-14	780-794	microparticles	abstract[41]|quantity[42]|abstract[45]	new[41]|new[42]|giv[45]	_	_
6-15	795-796	(	_	_	_	_
6-16	797-800	CD3	abstract	giv	coref	6-39[54_0]
6-17	801-802	,	_	_	_	_
6-18	803-807	CD19	abstract	new	_	_
6-19	808-809	)	_	_	_	_
6-20	810-813	has	_	_	_	_
6-21	814-818	been	_	_	_	_
6-22	819-827	observed	_	_	_	_
6-23	828-830	in	_	_	_	_
6-24	831-833	RA	organization|person[49]	new|new[49]	ana|coref	6-41[0_49]|6-45
6-25	834-842	patients	person[49]	new[49]	_	_
6-26	843-847	with	person[49]	new[49]	_	_
6-27	848-852	high	person[49]|abstract[51]	new[49]|giv[51]	coref	8-47[83_51]
6-28	853-860	disease	person[49]|abstract|abstract[51]	new[49]|giv|giv[51]	coref	8-36
6-29	861-869	activity	person[49]|abstract[51]	new[49]|giv[51]	_	_
6-30	870-871	.	_	_	_	_
6-31	872-886	Rodrigez-Cario	person	new	_	_
6-32	887-889	et	_	_	_	_
6-33	890-893	al.	_	_	_	_
6-34	894-902	examined	_	_	_	_
6-35	903-906	the	quantity[53]	new[53]	coref	8-27[74_53]
6-36	907-913	amount	quantity[53]	new[53]	_	_
6-37	914-916	of	_	_	_	_
6-38	917-928	circulating	_	_	_	_
6-39	929-943	microparticles	abstract[54]	giv[54]	_	_
6-40	944-947	and	abstract[54]	giv[54]	_	_
6-41	948-953	their	abstract[54]|person|abstract[56]	giv[54]|giv|new[56]	coref	6-44[58_0]
6-42	954-960	origin	abstract[54]|abstract[56]	giv[54]|new[56]	_	_
6-43	961-963	in	abstract[54]|abstract[56]	giv[54]|new[56]	_	_
6-44	964-967	114	abstract[54]|abstract[56]|person[58]	giv[54]|new[56]|giv[58]	coref	11-17[106_58]
6-45	968-970	RA	abstract[54]|abstract[56]|organization|person[58]	giv[54]|new[56]|giv|giv[58]	coref	8-14
6-46	971-979	patients	abstract[54]|abstract[56]|person[58]	giv[54]|new[56]|giv[58]	_	_
6-47	980-981	.	_	_	_	_

#Text=The total number of MPs in platelet poor plasma was much higher in individuals with arthritis compared to a group of healthy individuals .
7-1	982-985	The	quantity[59]	new[59]	_	_
7-2	986-991	total	quantity[59]	new[59]	_	_
7-3	992-998	number	quantity[59]	new[59]	_	_
7-4	999-1001	of	quantity[59]	new[59]	_	_
7-5	1002-1005	MPs	quantity[59]|quantity	new[59]|giv	coref	8-5
7-6	1006-1008	in	quantity[59]	new[59]	_	_
7-7	1009-1017	platelet	quantity[59]|object|object[62]	new[59]|giv|new[62]	_	_
7-8	1018-1022	poor	quantity[59]|object[62]	new[59]|new[62]	_	_
7-9	1023-1029	plasma	quantity[59]|object[62]	new[59]|new[62]	_	_
7-10	1030-1033	was	_	_	_	_
7-11	1034-1038	much	_	_	_	_
7-12	1039-1045	higher	_	_	_	_
7-13	1046-1048	in	_	_	_	_
7-14	1049-1060	individuals	person[63]	new[63]	coref	7-19[65_63]
7-15	1061-1065	with	person[63]	new[63]	_	_
7-16	1066-1075	arthritis	person[63]|abstract	new[63]|new	coref	14-18[134_0]
7-17	1076-1084	compared	_	_	_	_
7-18	1085-1087	to	_	_	_	_
7-19	1088-1089	a	person[65]	giv[65]	_	_
7-20	1090-1095	group	person[65]	giv[65]	_	_
7-21	1096-1098	of	person[65]	giv[65]	_	_
7-22	1099-1106	healthy	person[65]	giv[65]	_	_
7-23	1107-1118	individuals	person[65]	giv[65]	_	_
7-24	1119-1120	.	_	_	_	_

#Text=The occurrence of different MPs subtypes in this study differed considerably in the RA group and was associated with the clinical course of joint inflammation : The amount of endothelial MPs was associated with the disease duration , the amount of granulocyte MPs was associated with the disease activity as assessed by DAS28 , whereas the amount of monocyte-derived MPs was associated with the presence of the rheumatoid factor .
8-1	1121-1124	The	abstract[66]	new[66]	_	_
8-2	1125-1135	occurrence	abstract[66]	new[66]	_	_
8-3	1136-1138	of	abstract[66]	new[66]	_	_
8-4	1139-1148	different	abstract[66]|abstract[68]	new[66]|new[68]	_	_
8-5	1149-1152	MPs	abstract[66]|object|abstract[68]	new[66]|giv|new[68]	coref	8-30[76_0]
8-6	1153-1161	subtypes	abstract[66]|abstract[68]	new[66]|new[68]	_	_
8-7	1162-1164	in	abstract[66]|abstract[68]	new[66]|new[68]	_	_
8-8	1165-1169	this	abstract[66]|abstract[68]|abstract[69]	new[66]|new[68]|new[69]	coref	11-14[105_69]
8-9	1170-1175	study	abstract[66]|abstract[68]|abstract[69]	new[66]|new[68]|new[69]	_	_
8-10	1176-1184	differed	_	_	_	_
8-11	1185-1197	considerably	_	_	_	_
8-12	1198-1200	in	_	_	_	_
8-13	1201-1204	the	abstract[71]	new[71]	_	_
8-14	1205-1207	RA	organization|abstract[71]	giv|new[71]	coref	10-20
8-15	1208-1213	group	abstract[71]	new[71]	_	_
8-16	1214-1217	and	_	_	_	_
8-17	1218-1221	was	_	_	_	_
8-18	1222-1232	associated	_	_	_	_
8-19	1233-1237	with	_	_	_	_
8-20	1238-1241	the	abstract[72]	new[72]	_	_
8-21	1242-1250	clinical	abstract[72]	new[72]	_	_
8-22	1251-1257	course	abstract[72]	new[72]	_	_
8-23	1258-1260	of	abstract[72]	new[72]	_	_
8-24	1261-1266	joint	abstract[72]|abstract[73]	new[72]|new[73]	coref	15-51[0_73]
8-25	1267-1279	inflammation	abstract[72]|abstract[73]	new[72]|new[73]	_	_
8-26	1280-1281	:	_	_	_	_
8-27	1282-1285	The	quantity[74]	giv[74]	_	_
8-28	1286-1292	amount	quantity[74]	giv[74]	_	_
8-29	1293-1295	of	quantity[74]	giv[74]	_	_
8-30	1296-1307	endothelial	quantity[74]|person|object[76]	giv[74]|new|giv[76]	coref	8-42[81_76]
8-31	1308-1311	MPs	quantity[74]|object[76]	giv[74]|giv[76]	_	_
8-32	1312-1315	was	_	_	_	_
8-33	1316-1326	associated	_	_	_	_
8-34	1327-1331	with	_	_	_	_
8-35	1332-1335	the	abstract[78]	new[78]	_	_
8-36	1336-1343	disease	abstract|abstract[78]	giv|new[78]	coref	8-48
8-37	1344-1352	duration	abstract[78]	new[78]	_	_
8-38	1353-1354	,	_	_	_	_
8-39	1355-1358	the	quantity[79]	new[79]	_	_
8-40	1359-1365	amount	quantity[79]	new[79]	_	_
8-41	1366-1368	of	quantity[79]	new[79]	_	_
8-42	1369-1380	granulocyte	quantity[79]|person|object[81]	new[79]|new|giv[81]	coref	8-59[86_81]
8-43	1381-1384	MPs	quantity[79]|object[81]	new[79]|giv[81]	_	_
8-44	1385-1388	was	_	_	_	_
8-45	1389-1399	associated	_	_	_	_
8-46	1400-1404	with	_	_	_	_
8-47	1405-1408	the	abstract[83]	giv[83]	coref	10-20[102_83]
8-48	1409-1416	disease	abstract|abstract[83]	giv|giv[83]	coref	12-2
8-49	1417-1425	activity	abstract[83]	giv[83]	_	_
8-50	1426-1428	as	_	_	_	_
8-51	1429-1437	assessed	_	_	_	_
8-52	1438-1440	by	_	_	_	_
8-53	1441-1446	DAS28	object	new	coref	12-19
8-54	1447-1448	,	_	_	_	_
8-55	1449-1456	whereas	_	_	_	_
8-56	1457-1460	the	quantity[85]	new[85]	_	_
8-57	1461-1467	amount	quantity[85]	new[85]	_	_
8-58	1468-1470	of	quantity[85]	new[85]	_	_
8-59	1471-1487	monocyte-derived	quantity[85]|object[86]	new[85]|giv[86]	coref	9-4[0_86]
8-60	1488-1491	MPs	quantity[85]|object[86]	new[85]|giv[86]	_	_
8-61	1492-1495	was	_	_	_	_
8-62	1496-1506	associated	_	_	_	_
8-63	1507-1511	with	_	_	_	_
8-64	1512-1515	the	abstract[87]	new[87]	_	_
8-65	1516-1524	presence	abstract[87]	new[87]	_	_
8-66	1525-1527	of	abstract[87]	new[87]	_	_
8-67	1528-1531	the	abstract[87]|abstract[89]	new[87]|new[89]	_	_
8-68	1532-1542	rheumatoid	abstract[87]|abstract|abstract[89]	new[87]|new|new[89]	coref	14-18
8-69	1543-1549	factor	abstract[87]|abstract[89]	new[87]|new[89]	_	_
8-70	1550-1551	.	_	_	_	_

#Text=The amount of MPs was also associated with the presence of traditional cardiovascular risk factors .
9-1	1552-1555	The	quantity[90]	new[90]	coref	13-12[122_90]
9-2	1556-1562	amount	quantity[90]	new[90]	_	_
9-3	1563-1565	of	quantity[90]	new[90]	_	_
9-4	1566-1569	MPs	quantity[90]|abstract	new[90]|giv	coref	13-16[123_0]
9-5	1570-1573	was	_	_	_	_
9-6	1574-1578	also	_	_	_	_
9-7	1579-1589	associated	_	_	_	_
9-8	1590-1594	with	_	_	_	_
9-9	1595-1598	the	abstract[92]	new[92]	_	_
9-10	1599-1607	presence	abstract[92]	new[92]	_	_
9-11	1608-1610	of	abstract[92]	new[92]	_	_
9-12	1611-1622	traditional	abstract[92]|abstract[95]	new[92]|new[95]	_	_
9-13	1623-1637	cardiovascular	abstract[92]|abstract|abstract[95]	new[92]|new|new[95]	_	_
9-14	1638-1642	risk	abstract[92]|abstract|abstract[95]	new[92]|new|new[95]	_	_
9-15	1643-1650	factors	abstract[92]|abstract[95]	new[92]|new[95]	_	_
9-16	1651-1652	.	_	_	_	_

#Text=The findings of Cloutier et al. could indicate the possibility of using the studies of circulating mpICs to assess RA activity .
10-1	1653-1656	The	abstract[96]	new[96]	_	_
10-2	1657-1665	findings	abstract[96]	new[96]	_	_
10-3	1666-1668	of	abstract[96]	new[96]	_	_
10-4	1669-1677	Cloutier	abstract[96]|person	new[96]|new	_	_
10-5	1678-1680	et	abstract[96]	new[96]	_	_
10-6	1681-1684	al.	abstract[96]	new[96]	_	_
10-7	1685-1690	could	_	_	_	_
10-8	1691-1699	indicate	_	_	_	_
10-9	1700-1703	the	abstract[98]	new[98]	_	_
10-10	1704-1715	possibility	abstract[98]	new[98]	_	_
10-11	1716-1718	of	_	_	_	_
10-12	1719-1724	using	_	_	_	_
10-13	1725-1728	the	event[99]	giv[99]	_	_
10-14	1729-1736	studies	event[99]	giv[99]	_	_
10-15	1737-1739	of	_	_	_	_
10-16	1740-1751	circulating	_	_	_	_
10-17	1752-1757	mpICs	abstract	new	_	_
10-18	1758-1760	to	_	_	_	_
10-19	1761-1767	assess	_	_	_	_
10-20	1768-1770	RA	organization|abstract[102]	giv|giv[102]	coref|coref	11-24|12-1[110_102]
10-21	1771-1779	activity	abstract[102]	giv[102]	_	_
10-22	1780-1781	.	_	_	_	_

#Text=However , different conclusions were presented by van Eijk et al. based on a study with 24 patients with an early form of RA .
11-1	1782-1789	However	_	_	_	_
11-2	1790-1791	,	_	_	_	_
11-3	1792-1801	different	abstract[103]	new[103]	_	_
11-4	1802-1813	conclusions	abstract[103]	new[103]	_	_
11-5	1814-1818	were	_	_	_	_
11-6	1819-1828	presented	_	_	_	_
11-7	1829-1831	by	_	_	_	_
11-8	1832-1835	van	person[104]	new[104]	_	_
11-9	1836-1840	Eijk	person[104]	new[104]	_	_
11-10	1841-1843	et	_	_	_	_
11-11	1844-1847	al.	_	_	_	_
11-12	1848-1853	based	_	_	_	_
11-13	1854-1856	on	_	_	_	_
11-14	1857-1858	a	abstract[105]	giv[105]	_	_
11-15	1859-1864	study	abstract[105]	giv[105]	_	_
11-16	1865-1869	with	abstract[105]	giv[105]	_	_
11-17	1870-1872	24	abstract[105]|person[106]	giv[105]|giv[106]	coref	13-27[127_106]
11-18	1873-1881	patients	abstract[105]|person[106]	giv[105]|giv[106]	_	_
11-19	1882-1886	with	abstract[105]|person[106]	giv[105]|giv[106]	_	_
11-20	1887-1889	an	abstract[105]|person[106]|abstract[107]	giv[105]|giv[106]|new[107]	_	_
11-21	1890-1895	early	abstract[105]|person[106]|abstract[107]	giv[105]|giv[106]|new[107]	_	_
11-22	1896-1900	form	abstract[105]|person[106]|abstract[107]	giv[105]|giv[106]|new[107]	_	_
11-23	1901-1903	of	abstract[105]|person[106]|abstract[107]	giv[105]|giv[106]|new[107]	_	_
11-24	1904-1906	RA	abstract[105]|person[106]|abstract[107]|abstract	giv[105]|giv[106]|new[107]|giv	_	_
11-25	1907-1908	.	_	_	_	_

#Text=The disease activity was assessed based on the ESR , C-reactive protein ( CRP ) level , and DAS28 score .
12-1	1909-1912	The	abstract[110]	giv[110]	_	_
12-2	1913-1920	disease	abstract|abstract[110]	giv|giv[110]	coref	16-36
12-3	1921-1929	activity	abstract[110]	giv[110]	_	_
12-4	1930-1933	was	_	_	_	_
12-5	1934-1942	assessed	_	_	_	_
12-6	1943-1948	based	_	_	_	_
12-7	1949-1951	on	_	_	_	_
12-8	1952-1955	the	abstract[111]	new[111]	coref	15-4[0_111]
12-9	1956-1959	ESR	abstract[111]	new[111]	_	_
12-10	1960-1961	,	_	_	_	_
12-11	1962-1972	C-reactive	object|abstract[113]	new|new[113]	appos	12-14[0_113]
12-12	1973-1980	protein	abstract[113]	new[113]	_	_
12-13	1981-1982	(	_	_	_	_
12-14	1983-1986	CRP	abstract	giv	coref	15-6
12-15	1987-1988	)	_	_	_	_
12-16	1989-1994	level	quantity	new	coref	13-3[118_0]
12-17	1995-1996	,	_	_	_	_
12-18	1997-2000	and	_	_	_	_
12-19	2001-2006	DAS28	abstract|abstract[117]	giv|new[117]	coref	15-9
12-20	2007-2012	score	abstract[117]	new[117]	_	_
12-21	2013-2014	.	_	_	_	_

#Text=Moreover , the level of serum amyloid-P ( SAP ) and the amount of circulating MPs and MPs presenting the C1q complement component was determined in the patients .
13-1	2015-2023	Moreover	_	_	_	_
13-2	2024-2025	,	_	_	_	_
13-3	2026-2029	the	quantity[118]	giv[118]	_	_
13-4	2030-2035	level	quantity[118]	giv[118]	_	_
13-5	2036-2038	of	quantity[118]	giv[118]	_	_
13-6	2039-2044	serum	quantity[118]|abstract|abstract[120]	giv[118]|new|new[120]	_	_
13-7	2045-2054	amyloid-P	quantity[118]|abstract[120]	giv[118]|new[120]	_	_
13-8	2055-2056	(	_	_	_	_
13-9	2057-2060	SAP	substance	new	_	_
13-10	2061-2062	)	_	_	_	_
13-11	2063-2066	and	_	_	_	_
13-12	2067-2070	the	quantity[122]	giv[122]	coref	15-24[145_122]
13-13	2071-2077	amount	quantity[122]	giv[122]	_	_
13-14	2078-2080	of	_	_	_	_
13-15	2081-2092	circulating	_	_	_	_
13-16	2093-2096	MPs	quantity[123]	giv[123]	coref	15-29[0_123]
13-17	2097-2100	and	quantity[123]	giv[123]	_	_
13-18	2101-2104	MPs	quantity[123]	giv[123]	_	_
13-19	2105-2115	presenting	_	_	_	_
13-20	2116-2119	the	abstract[126]	new[126]	coref	15-34[149_126]
13-21	2120-2123	C1q	abstract|abstract[126]	new|new[126]	coref	15-36
13-22	2124-2134	complement	object|abstract[126]	new|new[126]	_	_
13-23	2135-2144	component	abstract[126]	new[126]	_	_
13-24	2145-2148	was	_	_	_	_
13-25	2149-2159	determined	_	_	_	_
13-26	2160-2162	in	_	_	_	_
13-27	2163-2166	the	person[127]	giv[127]	coref	14-1[128_127]
13-28	2167-2175	patients	person[127]	giv[127]	_	_
13-29	2176-2177	.	_	_	_	_

#Text=Nine patients were reassessed after an eight-week intensive treatment according to the COBRA ( COmBination therapy in Rheumatoid Arthritis ) regimen , which included a combined treatment with methotrexate , sulfasalazine , and prednisolone .
14-1	2178-2182	Nine	person[128]	giv[128]	_	_
14-2	2183-2191	patients	person[128]	giv[128]	_	_
14-3	2192-2196	were	_	_	_	_
14-4	2197-2207	reassessed	_	_	_	_
14-5	2208-2213	after	_	_	_	_
14-6	2214-2216	an	abstract[129]	giv[129]	coref	14-25[136_129]
14-7	2217-2227	eight-week	abstract[129]	giv[129]	_	_
14-8	2228-2237	intensive	abstract[129]	giv[129]	_	_
14-9	2238-2247	treatment	abstract[129]	giv[129]	_	_
14-10	2248-2257	according	abstract[129]	giv[129]	_	_
14-11	2258-2260	to	abstract[129]	giv[129]	_	_
14-12	2261-2264	the	abstract[129]|abstract[130]	giv[129]|new[130]	appos	14-14[132_130]
14-13	2265-2270	COBRA	abstract[129]|abstract[130]	giv[129]|new[130]	_	_
14-14	2271-2272	(	abstract[132]	giv[132]	_	_
14-15	2273-2284	COmBination	abstract|abstract[132]	new|giv[132]	_	_
14-16	2285-2292	therapy	abstract[132]	giv[132]	_	_
14-17	2293-2295	in	abstract[132]	giv[132]	_	_
14-18	2296-2306	Rheumatoid	abstract[132]|object|abstract[134]	giv[132]|giv|giv[134]	coref	16-21[0_134]
14-19	2307-2316	Arthritis	abstract[132]|abstract[134]	giv[132]|giv[134]	_	_
14-20	2317-2318	)	abstract[132]	giv[132]	_	_
14-21	2319-2326	regimen	abstract[132]|abstract	giv[132]|new	_	_
14-22	2327-2328	,	_	_	_	_
14-23	2329-2334	which	_	_	_	_
14-24	2335-2343	included	_	_	_	_
14-25	2344-2345	a	abstract[136]	giv[136]	coref	15-15[143_136]
14-26	2346-2354	combined	abstract[136]	giv[136]	_	_
14-27	2355-2364	treatment	abstract[136]	giv[136]	_	_
14-28	2365-2369	with	abstract[136]	giv[136]	_	_
14-29	2370-2382	methotrexate	abstract[136]|substance	giv[136]|new	_	_
14-30	2383-2384	,	abstract[136]	giv[136]	_	_
14-31	2385-2398	sulfasalazine	abstract[136]|substance	giv[136]|new	_	_
14-32	2399-2400	,	abstract[136]	giv[136]	_	_
14-33	2401-2404	and	abstract[136]	giv[136]	_	_
14-34	2405-2417	prednisolone	abstract[136]|substance	giv[136]|new	_	_
14-35	2418-2419	.	_	_	_	_

#Text=As expected , ESR , CRP , and DAS28 improved as a result of the treatment ; however , contrary to expectations , neither the amount of circulating MPs , nor MPs with the attached C1q component decreased , which suggests the absence of any connection between the activity of inflammation and MPs release and mpIC production .
15-1	2420-2422	As	_	_	_	_
15-2	2423-2431	expected	_	_	_	_
15-3	2432-2433	,	_	_	_	_
15-4	2434-2437	ESR	abstract	giv	_	_
15-5	2438-2439	,	_	_	_	_
15-6	2440-2443	CRP	object	giv	_	_
15-7	2444-2445	,	_	_	_	_
15-8	2446-2449	and	_	_	_	_
15-9	2450-2455	DAS28	abstract	giv	_	_
15-10	2456-2464	improved	_	_	_	_
15-11	2465-2467	as	_	_	_	_
15-12	2468-2469	a	_	_	_	_
15-13	2470-2476	result	_	_	_	_
15-14	2477-2479	of	_	_	_	_
15-15	2480-2483	the	abstract[143]	giv[143]	_	_
15-16	2484-2493	treatment	abstract[143]	giv[143]	_	_
15-17	2494-2495	;	_	_	_	_
15-18	2496-2503	however	_	_	_	_
15-19	2504-2505	,	_	_	_	_
15-20	2506-2514	contrary	_	_	_	_
15-21	2515-2517	to	_	_	_	_
15-22	2518-2530	expectations	abstract	new	_	_
15-23	2531-2532	,	_	_	_	_
15-24	2533-2540	neither	quantity[145]	giv[145]	_	_
15-25	2541-2544	the	quantity[145]	giv[145]	_	_
15-26	2545-2551	amount	quantity[145]	giv[145]	_	_
15-27	2552-2554	of	_	_	_	_
15-28	2555-2566	circulating	_	_	_	_
15-29	2567-2570	MPs	object	giv	coref	15-32[147_0]
15-30	2571-2572	,	_	_	_	_
15-31	2573-2576	nor	_	_	_	_
15-32	2577-2580	MPs	object[147]	giv[147]	coref	15-53[0_147]
15-33	2581-2585	with	object[147]	giv[147]	_	_
15-34	2586-2589	the	object[147]|abstract[149]	giv[147]|giv[149]	_	_
15-35	2590-2598	attached	object[147]|abstract[149]	giv[147]|giv[149]	_	_
15-36	2599-2602	C1q	object[147]|abstract|abstract[149]	giv[147]|giv|giv[149]	_	_
15-37	2603-2612	component	object[147]|abstract[149]	giv[147]|giv[149]	_	_
15-38	2613-2622	decreased	_	_	_	_
15-39	2623-2624	,	_	_	_	_
15-40	2625-2630	which	_	_	_	_
15-41	2631-2639	suggests	_	_	_	_
15-42	2640-2643	the	abstract[150]	new[150]	_	_
15-43	2644-2651	absence	abstract[150]	new[150]	_	_
15-44	2652-2654	of	abstract[150]	new[150]	_	_
15-45	2655-2658	any	abstract[150]|abstract[151]	new[150]|new[151]	_	_
15-46	2659-2669	connection	abstract[150]|abstract[151]	new[150]|new[151]	_	_
15-47	2670-2677	between	abstract[150]|abstract[151]	new[150]|new[151]	_	_
15-48	2678-2681	the	abstract[150]|abstract[151]|abstract[152]	new[150]|new[151]|new[152]	coref	16-35[171_152]
15-49	2682-2690	activity	abstract[150]|abstract[151]|abstract[152]	new[150]|new[151]|new[152]	_	_
15-50	2691-2693	of	abstract[150]|abstract[151]|abstract[152]	new[150]|new[151]|new[152]	_	_
15-51	2694-2706	inflammation	abstract[150]|abstract[151]|abstract[152]|abstract	new[150]|new[151]|new[152]|giv	_	_
15-52	2707-2710	and	abstract[150]|abstract[151]|abstract[152]	new[150]|new[151]|new[152]	_	_
15-53	2711-2714	MPs	abstract[150]|abstract[151]|abstract[152]|substance|event[155]	new[150]|new[151]|new[152]|giv|giv[155]	_	_
15-54	2715-2722	release	abstract[150]|abstract[151]|abstract[152]|event[155]	new[150]|new[151]|new[152]|giv[155]	_	_
15-55	2723-2726	and	abstract[150]|abstract[151]|abstract[152]	new[150]|new[151]|new[152]	_	_
15-56	2727-2731	mpIC	abstract[150]|abstract[151]|abstract[152]|object|abstract[157]	new[150]|new[151]|new[152]|new|giv[157]	_	_
15-57	2732-2742	production	abstract[150]|abstract[151]|abstract[152]|abstract[157]	new[150]|new[151]|new[152]|giv[157]	_	_
15-58	2743-2744	.	_	_	_	_

#Text=In a recent paper , Chen demonstrated that inhibition of PMPs formation in an animal model of CIA ( collagen-induced arthritis ) and reduction of circulating PMPs was associated with a clinical decrease in the disease activity assessed as joint swelling and stiffness .
16-1	2745-2747	In	_	_	_	_
16-2	2748-2749	a	abstract[158]	new[158]	_	_
16-3	2750-2756	recent	abstract[158]	new[158]	_	_
16-4	2757-2762	paper	abstract[158]	new[158]	_	_
16-5	2763-2764	,	_	_	_	_
16-6	2765-2769	Chen	person	new	_	_
16-7	2770-2782	demonstrated	_	_	_	_
16-8	2783-2787	that	abstract[160]	new[160]	_	_
16-9	2788-2798	inhibition	abstract[160]	new[160]	_	_
16-10	2799-2801	of	abstract[160]	new[160]	_	_
16-11	2802-2806	PMPs	abstract[160]|object|abstract[162]	new[160]|giv|new[162]	coref	16-27
16-12	2807-2816	formation	abstract[160]|abstract[162]	new[160]|new[162]	_	_
16-13	2817-2819	in	abstract[160]|abstract[162]	new[160]|new[162]	_	_
16-14	2820-2822	an	abstract[160]|abstract[162]|abstract[164]	new[160]|new[162]|new[164]	_	_
16-15	2823-2829	animal	abstract[160]|abstract[162]|person|abstract[164]	new[160]|new[162]|new|new[164]	_	_
16-16	2830-2835	model	abstract[160]|abstract[162]|abstract[164]	new[160]|new[162]|new[164]	_	_
16-17	2836-2838	of	abstract[160]|abstract[162]|abstract[164]	new[160]|new[162]|new[164]	_	_
16-18	2839-2842	CIA	abstract[160]|abstract[162]|abstract[164]|organization	new[160]|new[162]|new[164]|new	_	_
16-19	2843-2844	(	_	_	_	_
16-20	2845-2861	collagen-induced	_	_	_	_
16-21	2862-2871	arthritis	abstract	giv	_	_
16-22	2872-2873	)	_	_	_	_
16-23	2874-2877	and	_	_	_	_
16-24	2878-2887	reduction	abstract	giv	_	_
16-25	2888-2890	of	_	_	_	_
16-26	2891-2902	circulating	_	_	_	_
16-27	2903-2907	PMPs	object	giv	_	_
16-28	2908-2911	was	_	_	_	_
16-29	2912-2922	associated	_	_	_	_
16-30	2923-2927	with	_	_	_	_
16-31	2928-2929	a	event[169]	giv[169]	_	_
16-32	2930-2938	clinical	event[169]	giv[169]	_	_
16-33	2939-2947	decrease	event[169]	giv[169]	_	_
16-34	2948-2950	in	event[169]	giv[169]	_	_
16-35	2951-2954	the	event[169]|abstract[171]	giv[169]|giv[171]	_	_
16-36	2955-2962	disease	event[169]|abstract|abstract[171]	giv[169]|giv|giv[171]	_	_
16-37	2963-2971	activity	event[169]|abstract[171]	giv[169]|giv[171]	_	_
16-38	2972-2980	assessed	_	_	_	_
16-39	2981-2983	as	_	_	_	_
16-40	2984-2989	joint	_	_	_	_
16-41	2990-2998	swelling	_	_	_	_
16-42	2999-3002	and	_	_	_	_
16-43	3003-3012	stiffness	_	_	_	_
16-44	3013-3014	.	_	_	_	_
